Diabetic Macular Edema Before and After Intravitreal Triamcinolone Injection
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Purpose: To compare intravitreal triamcinolone acetonide (IVT) versus natural course in refractory diabetic macular edema. Methods: In a prospective interventional case series, twenty five eyes with refractory DME which had been allocated to the sham group of a previous clinical trial underwent new examination and optical coherence tomography about 9 months after their first enrollment. Twenty eyes that met the inclusion criteria, visual acuity (VA) < 20/50 and central macular thickness (CMT) > 200 µm, were treated by 4 mg IVT. Evaluations were repeated at 2 and 4 months post-injection to imitate the similar examination intervals after sham injection. Corrected visual acuity and macular thickness changes following IVT were compared to the corresponding changes after sham injection (the natural course). Results: Visual acuity changes within and between each period were not statistically significant. Visual acuity decreased 0.08 & 0.09 logMAR by 2 months and 0.06 & 0.04 logMAR by 4 months after sham and IVT injections, respectively. The changes of macular thickness after IVT and sham intervention were not meaningful either. However, the difference between thickness changes by 4 months (52±50 µm increase after sham vs. 262±115 μm reduction after IVT) was significant (P=0.014). Conclusions: Concerning macular thickness, IVT has beneficial effect on refractory diabetic macular edema as opposed to observation. However, considering visual acuity, it does not induce significant difference in comparison to the natural course of the disease.
참고문헌 (13)
- William E. Benson, "Diabetic Retinopathy", pp.30~ (2004)
- Ciardella AP, "Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study", 88, pp.1131~1136 (2004)
- Jonas JB, "Intravitreal injection of triamcinolone for diabetic macular edema", 121, pp.57~61 (2003)
- Martidis A, "Intravitreal triamcinolone for refractory diabetic macular edema", 109, pp.920~927 (2002)
- Cardillo JA, "Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema", 112, pp.1557~1563 (2005)
- Lam DS, "Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study", 32, pp.569~572 (2004)
- Krepler K, "The effect of intravitreal triamcinolone on diabetic macular oedema", 243, pp.478~481 (2005)
- Massin P, "Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial", 111, pp.218~224 (2004)
- Parolini B, "Diode laser, vitrectomy and intravitreal triamcinolone", 19, pp.1~12 (2004)
- Jonas JB, "Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study", 89, pp.321~326 (2005)
- Ozkiris A, "Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema", 14, pp.543~549 (2004)
- Jonas JB, "Intraocular pressure elevation after intravitreal triamcinolone acetonide injection", 112, pp.593~598 (2005)
- Larsson J, "Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone", 139, pp.802~806 (2005)